• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Should We Use Two Antidepressants to Treat Unipolar Depression?
RESEARCH UPDATE

Should We Use Two Antidepressants to Treat Unipolar Depression?

January 1, 2023
Paul Riordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Paul Riordan, MD. Dr. Riordan has no financial relationships with companies related to this material.

REVIEW OF: Henssler J et al, JAMA Psychiatry 2022;79(4):300–312

STUDY TYPE: Meta-analysis of randomized trials

Guidelines recommend a single antidepressant for nonpsychotic major depressive disorder, but is this the most effective approach? Or should we combine two antidepressants into a synergistic combination where the sum is greater than the parts? This meta-analysis seeks to answer these questions.

The authors identified 39 randomized trials lasting 3–12 weeks that compared dual antidepressant therapy to monotherapy for 6,751 patients with unipolar depression. They excluded maintenance trials. The primary outcome was the standardized mean difference (SMD, also known as effect size) of combination therapy compared to monotherapy. Secondary outcomes included remission rates, response rates, overall dropout rates, and dropout rates due to adverse events. The authors also performed several subgroup analyses to determine which combination of antidepressants worked best. 

Overall, there was a small benefit to combination therapy relative to monotherapy with an SMD of 0.31 (95% confidence interval [CI], 0.19–0.44), which roughly translates to a number needed to treat of 8–10. For the secondary outcomes, there was a 52% increase in odds of remission and a 40% increase in odds of response. Notably, there were no differences in the rates of overall dropouts or dropouts due to adverse events. 

So which combination should we use? Bupropion combinations failed to do better than monotherapy (SMD = 0.10; 95% CI, -0.07–0.27), while combinations involving the presynaptic α2-autoreceptors (specifically, augmentation with mirtazapine 7.5–45 mg/day, trazodone 100 mg/day, and mianserin 30–60 mg/day) did separate from placebo. The α2-autoreceptors were particularly effective when paired with an SSRI, SNRI, or tricyclic antidepressant (SMD = 0.37; 95% CI, 0.19–0.55). The authors suggest this combination as first-line treatment for severe cases of depression and for patients who do not respond to monotherapy.

These results conflict with other meta-analyses, which did not find a significant effect for mirtazapine augmentation, and the difference may lie in how the data were grouped (Zhou X et al, J Clin Psychiatry 2015;76(4):e487–e498). Nearly all of the large studies for the α2-autoreceptors were negative, while the positive results that tilted the balance came almost entirely from small studies involving fewer than 100 subjects. Specifically, all six large trials of mirtazapine augmentation were negative, as was the single large trial of mianserin augmentation. The two trazodone studies used a low dose of 100 mg, which is more in line with its use as a hypnotic than its antidepressant dose range, and neither of the studies tested the augmentation against placebo. 

While these results paint a mixed picture of mirtazapine in depression, there is evidence that mirtazapine augmentation helps associated symptoms of insomnia and anxiety (Rifkin-Zybutz R et al, J Psychopharmacol 2020;34(12):1342–1349).

CARLAT TAKE

Although this analysis finds a ray of hope for antidepressant combinations involving mirtazapine, trazodone, or the non-US antidepressant mianserin, that optimism is tempered by the negative results of large controlled trials. In practice, trazodone and mirtazapine may work best for associated symptoms of insomnia or—in the case of mirtazapine—anxiety.


General Psychiatry
    Paul Riordan, MD.

    Quetiapine Reconsidered

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Viibryd Goes Generic, But Is It Worth Prescribing?
    20 Years of The Carlat Report
    Aripiprazole-Related Psychotic Exacerbations
    Should We Use Two Antidepressants to Treat Unipolar Depression?
    DBT Skills May Reduce Polypharmacy in Borderline Personality Disorder
    Pimavanserin Improves Negative Symptoms of Schizophrenia
    CME Post-Test, Psychiatric Education, TCPR, January 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_cover_sm.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • shutterstock_495683782.jpg
      General Psychiatry

      The Other Freud 1

      Sigmund Freud’s theories are challenged by his granddaughter, Sophie Freud.



      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.